Charter of the Science, Technology and Clinical Affairs Committee

PURPOSE AND POLICY

The purpose of the Science, Technology and Clinical Affairs Committee (the "***Committee***") of the Board of Directors (the "***Board***") of Talis Biomedical Corporation (the "***Company***") is to review and advise the Board on the Company's research and development programs, its technology and relevant scientific advances.

COMPOSITION

The Committee shall consist of three or more members of the Board. Each member shall, in the judgment of the Board, have scientific, medical or other expertise relevant to the Company's business. The Committee members shall be appointed by and serve at the discretion of the Board. Resignation or removal of a Committee member from the Board shall immediately constitute resignation or removal, as applicable from the Committee. Vacancies occurring on the Committee shall be filled by the Board. The Committee's chairperson shall be designated by the Board or, if it does not do so, the Committee members shall elect a chairperson by vote of a majority of the full Committee. The Chair (or in his or her absence, a member designated by the Chair) shall preside at all meetings of the Committee.

MEETINGS AND MINUTES

The Committee shall hold such regular or special meetings as its members deem necessary or appropriate, but in no event less than annually. The presence in person or by telephone of a majority of the Committee's members shall constitute a quorum for any meeting of the Committee. All actions of the Committee will require (i) the vote of a majority of the members present at a meeting of the Committee at which a quorum is present or (ii) unanimous written consent of the members of the Committee then serving. Minutes of each meeting will be kept and distributed to each member of the Committee, members of the Board who are not members of the Committee and the Secretary of the Company. The Chair of the Committee will report to the Board from time to time or whenever so requested by the Board.

RESPONSIBILITIES AND AUTHORITY

The Committee shall have full access to all books, records, facilities and personnel of the Company as deemed necessary or appropriate by any member of the Committee to discharge his or her responsibilities hereunder. The Committee shall have the authority to obtain, at the expense of the Company, advice and assistance from external advisors and consultants. Other reasonable expenditures for external resources that the Committee deems necessary or appropriate in the performance of its duties are permitted. The operation of the Committee shall be subject to the Bylaws of the Company as in effect from time to time and Section 141 of the Delaware General Corporation Law. The approval of this Charter by the Board shall be construed as a delegation of authority to the Committee with respect to the responsibilities set forth herein.

To implement the Committee's purpose, the Committee shall be charged with the following functions and processes with the understanding, however, that the Committee may supplement or (except as otherwise required by applicable laws or rules) deviate from these activities as appropriate under the circumstances:

1. ***Technical Initiatives.*** The Committee shall review and assess current and planned research and development programs and technology initiatives from a scientific perspective, and from time to time provide observations and strategic recommendations to the Board.

2. ***Research and Development Personnel.*** The Committee shall assess the capabilities of the Company's key scientific personnel, and the depth and breadth of the Company's scientific resources, as well as provide guidance on the recruitment and retention of scientific personnel.

3. ***Trends and Developments.*** The Committee shall periodically review, make recommendations to the Board and monitor significant emerging regulatory, research, scientific, and medical developments, processes, procedures, trends and competitive activity relevant to the Company's research and development strategy and preclinical and clinical trial programs, including their potential impact on the Company's programs, plans or policies.

4. ***Annual Evaluation and Charter Review.*** The Committee shall review, discuss and assess its own performance at least annually. The Committee shall also review and assess the adequacy of this charter at least annually and shall recommend any proposed changes to the Board for its consideration and approval.